Beacon Investment Advisory Services Inc. Sells 5,951 Shares of Stryker Corporation $SYK

Beacon Investment Advisory Services Inc. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 10.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 49,723 shares of the medical technology company’s stock after selling 5,951 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Stryker were worth $15,655,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Varma Mutual Pension Insurance Co raised its stake in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after acquiring an additional 5,100 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares in the last quarter. Swedbank AB boosted its stake in shares of Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares during the last quarter. Finally, Cibc World Market Inc. grew its holdings in shares of Stryker by 11.9% during the 4th quarter. Cibc World Market Inc. now owns 157,822 shares of the medical technology company’s stock valued at $55,470,000 after purchasing an additional 16,790 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. Citigroup restated an “outperform” rating on shares of Stryker in a report on Monday. Finally, Needham & Company LLC decreased their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Price Performance

Shares of Stryker stock opened at $338.85 on Friday. The company’s fifty day simple moving average is $320.11 and its two-hundred day simple moving average is $334.13. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a market cap of $129.97 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 2.15 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is presently 36.48%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.